Background: The correlation between computed tomography (CT)-based tracheal size and spirometry values is unknown in patients with tracheal stenosis by thoracic malignancy, which is often treated by tracheal stenting. Objectives: To evaluate the correlation between the tracheal cross-sectional area (CSA) and spirometric values before and after tracheal stenting, and to confirm that greater improvement in tracheal CSA leads to a larger improvement in spirometry values. Methods: A total of 32 patients with malignant tracheal stenosis underwent tracheal stenting. Before (n = 32) and after (n = 27) treatment, patients underwent chest CT, measuring mean and minimum tracheal CSA values, and spirometry. The correlation between tracheal CSA and each spirometric value was evaluated using Spearman rank correlation analysis. Differences in the pre-and posttreatment tracheal CSA and spirometric values were evaluated using the Wilcoxon matched-pairs test. Results: Significant improvement in the minimum tracheal CSA and in spirometric values was observed after stenting (P < 0.001). Pretreatment analysis revealed significant correlations between the minimum tracheal CSA and various spirometric values (P < 0.01), but posttreatment analysis showed weak or insignificant correlations. The increase in the minimum tracheal CSA obtained by stenting was significantly correlated with improvement in multiple spirometric values (P < 0.05). Conclusions: The tracheal size measured on chest CT correlates with patients' spirometric values, particularly at the prestenting examination, How to cite this paper: Azagami, S., Yamashiro, T., Handa, H., Inoue, T., Matsuoka, S., Miyazawa, T. and Mineshita, M. 
Introduction
Tracheal stenosis is often caused by thoracic malignancy, typically by direct tracheal invasion of primary cancers, external tracheal compression by lymph node metastases, and luminal narrowing by endoluminal tracheal malignancies. Malignant tracheal stenoses frequently cause dyspnea and asphyxia, resulting in high morbidity and mortality. It has been reported that more than 50% of patients with advanced-stage lung cancer have some extent of stenosis in the central airways [1] . A simulation analysis and a bronchoscopic study measuring intratracheal pressure showed that constriction of over 70% of the tracheal lumen causes severe airflow reduction [2] [3] .
Although they are usually palliative treatments, bronchoscopic interventions have been developed for and used in symptomatic patients with malignant tracheal stenosis. Multiple studies have shown that tracheal stenting is very effective for the relief of symptoms and for prolonging survival [3] - [11] . Previous studies analyzing patients with central airway stenosis showed that stent placement at the flow-limiting point of the target airway provides significant improvement in pulmonary function and relief of symptoms [3] [8] [11] . Combining pulmonary function tests (PFTs), computed tomography (CT), and bronchoscopy, is considered beneficial in evaluating the severity of stenosis and the effect of tracheal stenting [3] [11]- [16] .
While it has already been shown that statistically significant improvement in spirometric values is observed after intra-airway stenting for patients with malignant tracheobronchial stenoses [8] , there is no previous analysis that evaluates the statistical correlation between quantitatively measured tracheal size and spirometric values in patients with malignant tracheal stenosis. However, these correlations have been noted in patients with relapsing polychondritis (RP).
Usuba et al. clearly demonstrated that RP patients with more severe tracheal stenosis, as measured on chest CT, have worse spirometric values, particularly at end-expiration [17] . While it still is controversial whether small or collapsed proximal airways on chest CT are truly morbid in patients with chronic obstructive pulmonary disease (COPD) [18] [19] [20] [21] , there are significant positive correlations between CT-based tracheal size and spirometric values in patients with RP [17] .
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Based on these observations, we hypothesize that there would also be significant correlations between tracheal size, as measured on chest CT, and spirometric values in patients with malignant tracheal stenosis. Further, we predict that enlargement of the trachea by stenting would correlate with improvement in spirometric values. The aim of our study is 1) to evaluate the correlation between the cross-sectional area (CSA) of the trachea on chest CT and spirometric values in patients with malignant tracheal stenosis, before and after tracheal stenting; 2) to evaluate the correlation between an increase in tracheal CSA after stenting and improvement in spirometric values.
Materials and Methods
This retrospective study was approved by the institutional review board at St.
Marianna University School of Medicine, which waived the need for written informed consent.
Subjects
We reviewed the medical records and previous chest CT images of all patients who underwent implantation of a tracheal stent between April 2005 and April 2016. Forty-two patients were identified who had malignant tracheal stenosis and underwent tracheal stenting with pretreatment chest CT and PFT. All patients had severe tracheal stenosis caused by a malignant neoplasm and subjective symptoms related to the stenosis.
The exclusion criteria were severe stenosis and occlusion found at the main bronchus, not treated by tracheal stenting (n = 7), and pretreatment chest CT performed at another institution (n = 3). A total of 32 patients (20 men and 12 women, with a mean age of 63 years [range, 38 -85 years]) were ultimately included in this study. The included patients had tracheal stenosis caused by lung cancer (n = 16), esophageal cancer (n = 6), thyroid cancer (n = 4), primary tracheal cancer (n = 1), laryngeal cancer (n = 1), and intratracheal or lymph node metastases from abdominal or pelvic cancer (rectal cancer, n = 2; uterine cervical cancer, n = 1; ureteral cancer, n = 1). Of the 32 patients, 27 underwent chest CT and PFT after stenting. The patient characteristics and PFT results are summarized in Table 1 . Of the 32 patients, 26 (81%) were current or previous smokers (10 current smokers and 16 previous smokers; mean smoking index, 32.7 packyears).
CT Scanning
All patients were scanned using a 64-row or 80-row detector CT scanners (Aquilion 64 or Aquilion PRIME; Toshiba Medical Systems, Otawara, Tochigi, Japan).
Chest CT was performed in the supine position during breath hold at full inspiration. The scanning parameters were as follows: collimation, 0.5 mm; tube voltage, 120 kVp; gantry rotation time, 0.5 seconds; beam pitch, 0.828 (Aquilion 64) or 0.813 (Aquilion PRIME). At pretreatment imaging using the Aquilion 64 Open Journal of Medical Imaging machine, 17 patients were scanned using a fixed tube current setting of 200 mA, and 8 patients were scanned using other fixed tube current settings (100 -350 mA). The tube current for the Aquilion PRIME scanner (n = 7) was varied using automatic exposure control. At posttreatment imaging, the tube current setting for the Aquilion 64 scanner was fixed at 200 mA in 18 patients, and other settings were used in 5 patients (100 -150 mA). As in pretreatment imaging, the tube current was varied during posttreatment imaging with the Aquilion PRIME scanner, using automatic exposure control (n = 4). All images were reconstructed using a standard algorithm (FC04) with a slice thickness of 7 mm. The imaging field of view was 320 mm, and the pixel size was 0.625 × 0.625 mm. A contrast medium was used for 6 patients at prestenting imaging and for 2 at poststenting imaging.
CT Analysis: Measurement of Tracheal CSA
Tracheal CSA measurement followed the methods used by a previous study, including the use of an open-source image-processing program (Image J, version 1.48; http://imagej.nih.gov/ij/) [17] [19] . A pulmonologist (S.A) with 5 years of experience in respiratory medicine performed the measurements, after being coached by an experienced radiologist familiar with the method (T.Y) with 15 years of experience in thoracic radiology). First, all axial CT images that included the intrathoracic trachea (from the top of the apex to the carina) were selected (between 9 and 11 images, depending on the patient's body habitus). Open Journal of Medical Imaging Second, the tracheal lumen on each image was extracted from the surrounding structures using a semiautomatic threshold technique (between −500 and −1024 Hounsfield Units [HU] ). Finally, the extracted tracheal lumen was measured as the tracheal CSA on all selected images, and the mean and minimum tracheal CSAs were obtained. These measurement processes were applied to both pretreatment and posttreatment scans.
CT Analysis: Measurement of Emphysema
As an index for the extent of pulmonary emphysema, the low attenuation area percentage (LAA%) was automatically measured using open-source software (Airway Inspector; Boston, MA; http://airwayinspector.acil-bwh.org/) [19] . In brief, the software segmented the lung parenchyma (between −500 and −1024 HU) from the chest wall and the hilum, created a density histogram of the lung parenchyma, and measured LAA% (<−950 HU). The LAA% measurements were performed using the prestenting CT unless that scan was enhanced. For the 6 patients whose prestenting CT scans were enhanced, the poststenting scans without contrast were analyzed instead. Thus, LAA% was measured using plain CT data in all patients.
Pulmonary Function Testing
All 32 subjects performed pretreatment spirometry within 2 weeks of the pretreatment CT. After stenting, 27 patients underwent posttreatment spirometry within 2 weeks of the posttreatment CT. Spirometry was performed according to the protocol of the European Respiratory Society [22] . The measurements in- Table 1 .
Tracheal Stenting
All subjects were intubated using a rigid bronchoscope (EFER-Dumon; EFER Medical, La Ciotat, France) under general anesthesia. A total of 17 patients received a Spiral Z stent (Medico's Hirata, Inc., Osaka, Japan), 6 received an Ultraflex stent (Boston Scientific, Marlborough, MA, USA), 5 received a Tracheobronxane-Dumon stent (Novatech, Grasse, France), 1 received a TM stent (Fuji systems, Tokyo, Japan) and 3 received an AERO stent (Merit Medical Endotek, South Jordan, UT, USA).
The Spiral Z stent, an improved model of the Gianturco Z stent (Cook Medical, Inc., Bloomington, IN, USA), was a continuous loop stent of stainless steel wire; this stent was uncovered and self-expanding. The Ultraflex stent was a self-expanding, metallic stent made of nitinol; this stent had both covered and uncovered types. The Tracheobronxane-Dumon stent and TM stent were sili-Open Journal of Medical Imaging cone stents for central airway stenosis; it could be customized for length, shape, and diameter, and as a fully covered stent, was not self-expanding. The AERO stent was a hybrid stent that consisted of a covered piece of nitinol. Hybrid airway stents were designed to remedy the drawbacks of conventional silicone or metallic stents. This stent was fully covered and self-expanding. The selection of stent at time of bronchoscopic intervention was made by the interventional pulmonologists, based on the bronchoscopic appearance of severity and stenosis.
Statistical Analysis
The correlation of tracheal CSA measurements or LAA% measurements with spirometric values was determined using Spearman rank correlation analysis.
The differences in values between pre-and poststenting spirometry and tracheal CSA were judged using the Wilcoxon matched-pairs test. All statistical analyses were performed using JMP software, version 12.0 (SAS Institute, Cary, NC).
Continuous data were expressed as the mean ± standard deviation. For all statistical analyses, a P value of less than 0.05 was considered statistically significant.
Results

Pulmonary Function Testing
The mean values of all spirometric values, except for the FVC, increased from prestenting to poststenting examination. For the 27 patients with poststentingspirometric data available, significant increases in FEV 1 , FEV 1 /FVC, FEF 25-75% , and PEF values were confirmed after tracheal stenting (P < 0.001) ( Table 1) .
Tracheal Measurement
The minimum tracheal CSA was 40.5 ± 18.2 mm 2 before stenting (n = 32) and 86.8 ± 40.5 mm 2 after stenting (n = 27), while the mean tracheal CSA was 154.4 ± 60.7 mm 2 before stenting (n = 32) and 151.7 ± 49.6 mm 2 after stenting (n = 27).
For 27 patients with poststenting data available, a significant increase in the minimum tracheal CSA was confirmed after stenting (P < 0.0001).
Correlation between Tracheal Measurement and Spirometric Values before Stenting (n = 32)
The pretreatment tracheal CSA measurements and their correlations with spirometric values are given in Table 2 . The minimum tracheal CSA was signifi- Table   2 ). These data suggest that the most stenotic point of the trachea is the most powerful inhibitor for obstructive conditions. 
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Correlation between Tracheal Measurement and Spirometric Values after Stenting (n = 27)
The posttreatment tracheal CSA measurements and their correlations with spirometric values are given in Table 3 . In contrast to the prestenting results, the minimum tracheal CSA showed a weak correlation with FEV 1 and PEF values Open Journal of Medical Imaging only (P < 0.05). A similarly weak correlation between the mean tracheal CSA and these spirometric values was noted (Table 3) . Although there were some tendencies toward a positive relation between the tracheal CSA and other spirometric values, they were not statistically significant. Table 4 shows the correlations between the differences in tracheal size and the differences in spirometric values, comparing prestenting with poststenting data (n = 27). Significant positive correlations were found between the increase in the minimum tracheal CSA and the improvements in some spirometric values (FEV 1 , FEV 1 % predicted, FEV 1 /FVC, and PEF; ρ = 0.397 -0.594; P < 0.05).
Correlation between Increase in Tracheal Size and Improvement in Spirometric Values
These observations suggest that the more expanded trachea created by the stent resulted in a larger improvement in PFT values ( Figure 2 and Figure 3 ). Table 3 . Posttreatment tracheal cross-sectional area and correlation with posttreatment spirometry (n = 27).
CT measurement Correlation coefficient (ρ) for spirometric value Table 4 . Correlation between the difference in the minimum tracheal cross-sectional area and the differences in spirometric values, comparing pretreatment with posttreatment data (n = 27). 
Emphysema Measurement Had No Correlation to Spirometric Values
The mean LAA% was 2.2% ± 4.5% (range, 0% -18.7%). No correlation was observed between LAA% and prestenting or poststenting spirometric values ( Table  2 and Table 3 ). Thus, in this study population, we determined that the influence of tracheal stenosis was more important for airflow limitation than the presence of either emphysema or COPD. Interestingly, all correlation coefficients with various spirometric values were larger at poststenting than at prestenting examination, which may imply that the effect of emphysema on airflow limitation is increased after tracheal stenosis is relieved by stenting.
Discussion
We spirometry cannot be performed correctly and the resulting data are unreliable.
In such a situation, as is shown in our study, chest CT can be used as an alternative to spirometry to provide objective analysis; CT can be a good indicator of progression or severity of tracheal stenosis. We therefore recommend that the choice to use either spirometry, chest CT, or both should be based on each pa- There are several important limitations to our study. First, the total number of patients was small, particularly for the poststenting analysis, and the number of Open Journal of Medical Imaging analyzed patients was different at pretreatment and posttreatment examinations.
Second, we included various types of malignant tracheal stenosis such as direct invasion by lung cancer and external compression by lymph node metastases.
Ideally, these various causes of tracheal stenoses would be categorized into subgroups; however, subgroup analysis was not feasible in our small study. Third, since different types of tracheal stents were used, we cannot deny the influence of the type of stent or stent matrix on posttreatment tracheal CSA measurement.
Although we confirmed that severe metallic artifacts did not exist on poststenting CT, the reliability of poststenting tracheal CSA measurements should be examined in a future study with a larger number of patients. Fourth, we did not evaluate the long-term outcomes of tracheal stenting. Since it is already known that the stent occasionally causes another airway stenosis around its peripheral edge, it may be insufficient to evaluate posttreatment CT and spirometry immediately after stenting without further follow-up. Fifth, we did not evaluate expiratory CT. It has been reported that the expiratory minimum tracheal CSA strongly correlates with spirometric values in patients with RP [17] . We may have found stronger correlations between tracheal CSA and spirometric values if expiratory CT images had been available. Sixth, the CT scanners and protocols
were not standardized. Tracheal measurements should be robust, even with different CT settings, but the LAA% measurement is more sensitive and more easily influenced by unstandardized CT protocols.
In conclusion, the tracheal CSA measured on chest CT significantly correlates with spirometric values, particularly at prestenting examination, and an increase in the minimum tracheal CSA weakly correlates with an improvement in spirometric values after stenting. These observations can be expanded as clinical predictors of lung function in patients with malignant tracheal stenosis.
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